Objective: The goal of this study is to determine the effect of oral Tarooneh on post lumbar disc surgery pain and prevention of severe pain-related complications and reduction of treatment costs and hospitalization period. Design of the study: a Randomized (with the Block of size 4), double blind, controlled, single-centered, phase 2 trial. Study population: Patients with lumbar disc disease. Inclusion criteria: Having discopathy without fusion. Exclusion criteria: Unwillingness to attend the study. Sample size: 70. Intervention or interventions: After receiving an informed consent and filling a questionnaire, the pain (by VAS) and vital signs will be measured one hour before the first dose of pain killer. Then, Tarooneh will be delivered to the patients in intervention group, 5 cc, 6, 12 and 24 hours after surgery (3 times) in addition to the usual treatments. The control group will receive the placebo instead of Tarooneh. One hour after receiving each dose, the pain status using Visual Analog Scale (VAS) and vital signs will be evaluated. Main outcome variables: Primary outcome: Pain Secondary outcomes: Blood pressure, Pulse rate, Breathing rate, temperature.